
InvenTrust Properties Corp. operates as a leading multi-tenant retail real estate investment trust (REIT), engaging in the acquisition, ownership, leasing, redevelopment, and management of properties. Its portfolio largely comprises grocery-anchored neighborhood centers, along with some power centers that often include a grocery store, primarily located in demographically robust Sun Belt markets. The company is committed to advancing its multi-tenant retail platform by strategically investing in essential grocery-anchored assets within its current regions, consistently employing a focused and disciplined capital allocation strategy.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does InvenTrust Properties (IVT) have what it takes?

DOWNERS GROVE, Ill.--(BUSINESS WIRE)--InvenTrust Properties Corp. (“InvenTrust” or the “Company”) (NYSE: IVT) will report its second quarter 2026 earnings results on August 3, 2026, after the market closes. The Company's earnings release and any supplemental information will be posted on the Investor Relations section of the Company's website – www.inventrustproperties.com/investor-relations/. InvenTrust will host an earnings conference call to discuss the Company's results and business highlig.

InvenTrust Properties (IVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does InvenTrust Properties (IVT) have what it takes?

JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.